Chronic administration of an alpha 2 adrenergic agonist desensitizes rats to the anesthetic effects of dexmedetomidine. 1994

K Reid, and Y Hayashi, and T Z Guo, and C Correa-Sales, and C Nacif-Coelho, and M Maze
Department of Anesthesia, Standford University School of Medicine, CA 94305.

alpha 2 adrenergic agonists are being administered perioperatively to facilitate the anesthetic management of the surgical patient. In some clinical settings, use of alpha 2 adrenergic agonists has been extended into the postoperative period to prolong the patients' sedative and stress-free state. We studied whether the administration of alpha 2 adrenergic agonists over an extended period of time would result in "desensitization" to the central actions of alpha 2 adrenergic agonists. Male Sprague-Dawley rats were administered dexmedetomidine, a highly selective alpha 2 adrenergic agonist, at rates varying between 1 and 10 micrograms.kg-1.h-1 via a chronically implanted SC osmotic pump. Spontaneous locomotor activity, tested in an open-field box, was significantly lower in both 3- and 10-micrograms.kg-1.h-1 treatment groups but returned to normal by the second or sixth day, respectively. The hypnotic response to dexmedetomidine IP was decreased in the 10-micrograms.kg-1.h-1 dose group from the second day, and by the fourth day in the 3-micrograms.kg-1.h-1 group. Recovery from the desensitized state was rapid and occurred on the third day after pump removal in the 3-micrograms.kg-1.h-1 group and by the fifth day after pump removal in the 10-micrograms.kg-1.h-1 dose group. By using a higher dose of dexmedetomidine IP (250 micrograms.kg in lieu of 100 micrograms/kg) at day 7 in "tolerant" rats, the hypnotic response could partially be "restored" towards normal. An attenuated hypnotic response could still be demonstrated even when dexmedetomidine was administered directly into the locus coeruleus (LC) in rats pretreated chronically with dexmedetomidine.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D006993 Hypnotics and Sedatives Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. Hypnotic,Sedative,Sedative and Hypnotic,Sedatives,Hypnotic Effect,Hypnotic Effects,Hypnotics,Sedative Effect,Sedative Effects,Sedatives and Hypnotics,Effect, Hypnotic,Effect, Sedative,Effects, Hypnotic,Effects, Sedative,Hypnotic and Sedative
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D004856 Postural Balance A POSTURE in which an ideal body mass distribution is achieved. Postural balance provides the body carriage stability and conditions for normal functions in stationary position or in movement, such as sitting, standing, or walking. Postural Control,Posture Balance,Posture Control,Posture Equilibrium,Balance, Postural,Musculoskeletal Equilibrium,Postural Equilibrium,Balance, Posture,Control, Postural,Control, Posture,Equilibrium, Musculoskeletal,Equilibrium, Postural,Equilibrium, Posture,Postural Controls,Posture Balances,Posture Controls,Posture Equilibriums
D006221 Halothane A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. NITROUS OXIDE is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) 1,1,1-Trifluoro-2-Chloro-2-Bromoethane,Fluothane,Ftorotan,Narcotan
D000316 Adrenergic alpha-Agonists Drugs that selectively bind to and activate alpha adrenergic receptors. Adrenergic alpha-Receptor Agonists,alpha-Adrenergic Receptor Agonists,Adrenergic alpha-Agonist,Adrenergic alpha-Receptor Agonist,Receptor Agonists, Adrenergic alpha,Receptor Agonists, alpha-Adrenergic,alpha-Adrenergic Agonist,alpha-Adrenergic Agonists,alpha-Adrenergic Receptor Agonist,Adrenergic alpha Agonist,Adrenergic alpha Agonists,Adrenergic alpha Receptor Agonist,Adrenergic alpha Receptor Agonists,Agonist, Adrenergic alpha-Receptor,Agonist, alpha-Adrenergic,Agonist, alpha-Adrenergic Receptor,Agonists, Adrenergic alpha-Receptor,Agonists, alpha-Adrenergic,Agonists, alpha-Adrenergic Receptor,Receptor Agonist, alpha-Adrenergic,Receptor Agonists, alpha Adrenergic,alpha Adrenergic Agonist,alpha Adrenergic Agonists,alpha Adrenergic Receptor Agonist,alpha Adrenergic Receptor Agonists,alpha-Agonist, Adrenergic,alpha-Agonists, Adrenergic,alpha-Receptor Agonist, Adrenergic,alpha-Receptor Agonists, Adrenergic
D000777 Anesthetics Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. Anesthetic,Anesthetic Agents,Anesthetic Drugs,Anesthetic Effect,Anesthetic Effects,Agents, Anesthetic,Drugs, Anesthetic,Effect, Anesthetic,Effects, Anesthetic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats

Related Publications

K Reid, and Y Hayashi, and T Z Guo, and C Correa-Sales, and C Nacif-Coelho, and M Maze
June 1998, Anesthesiology,
K Reid, and Y Hayashi, and T Z Guo, and C Correa-Sales, and C Nacif-Coelho, and M Maze
September 1996, Anesthesia and analgesia,
K Reid, and Y Hayashi, and T Z Guo, and C Correa-Sales, and C Nacif-Coelho, and M Maze
October 1990, Journal of cardiovascular pharmacology,
K Reid, and Y Hayashi, and T Z Guo, and C Correa-Sales, and C Nacif-Coelho, and M Maze
October 1991, Neuropharmacology,
K Reid, and Y Hayashi, and T Z Guo, and C Correa-Sales, and C Nacif-Coelho, and M Maze
August 1992, Journal of cardiothoracic and vascular anesthesia,
K Reid, and Y Hayashi, and T Z Guo, and C Correa-Sales, and C Nacif-Coelho, and M Maze
June 1997, The American journal of physiology,
K Reid, and Y Hayashi, and T Z Guo, and C Correa-Sales, and C Nacif-Coelho, and M Maze
December 1988, Anesthesiology,
K Reid, and Y Hayashi, and T Z Guo, and C Correa-Sales, and C Nacif-Coelho, and M Maze
February 1991, Pharmacology & toxicology,
K Reid, and Y Hayashi, and T Z Guo, and C Correa-Sales, and C Nacif-Coelho, and M Maze
July 1988, Anesthesia and analgesia,
K Reid, and Y Hayashi, and T Z Guo, and C Correa-Sales, and C Nacif-Coelho, and M Maze
May 1988, Anesthesiology,
Copied contents to your clipboard!